Luxehomezone Introduces Elegant New Chandelier Collections, Redefining Luxury Home LightingTrump’s DEA nominee withdraws from consideration just days after being picked
(Bloomberg) -- Arm Holdings Plc’s legal dispute with Qualcomm Inc. is being argued before a federal jury in Delaware this week, pitting two of the world’s most influential chipmakers against each other in an intellectual property case that threatens to roil the technology industry. Qualcomm is one of Arm’s biggest customers and a longtime partner, but they’ve grown increasingly at odds. At the heart of this legal fight is Qualcomm’s 2021 acquisition of chip startup Nuvia and a licensing agreement to use Arm’s technology. Arm claims the agreement it had with Nuvia had to be renegotiated after Qualcomm bought the company, and it demanded Qualcomm destroy the chip designs gained from the acquisition. Qualcomm, which is counting on Nuvia products to push into the market for computer processors, argued it already had a separate licensing contract for Arm technology that covers its work. The dispute has riveted the chip industry. Many of the world’s biggest tech companies rely on technology licensed from Arm and Qualcomm to make products, so the trial could have far-reaching implications. “They wanted to take the code, but they didn’t want to pay for it,” Arm lawyer Daralyn Durie told jurors during opening arguments Monday. The trial is expected to last a week. Qualcomm lawyer Karen Dunn said the company had its own license to use Arm technology, and that it had always made it a practice to “respect contracts.” Internal files at Arm showed executives there acknowledged Qualcomm’s licensing contract was “bombproof,” she said. UK-based Arm, which is majority-owned by Japan’s SoftBank Group Corp., sells chip designs and licenses a so-called instruction set — code used by software to communicate with processors. Arm says it negotiates contract terms for use of its technology with companies on an individual basis. Startups like Nuvia typically get less burdensome financial terms than established businesses such as Qualcomm, which argues that its own license is broad enough to cover the intellectual property in question. Arm moved to cancel Qualcomm’s license this year, saying the US company never renegotiated terms after the Nuvia acquisition. Qualcomm countered that it hasn’t done anything wrong and that Arm is trying to unfairly bully it into paying more. Both companies declined to comment before the trial. Besides the dispute over the license – worth an estimated $1.5 billion – the case highlights the growing rivalry between two companies that previously had been tightly aligned. Qualcomm is the biggest chip supplier to the mobile-phone market. Arm’s technology is incorporated into most of those chips. CEOs to Testify Arm — under Chief Executive Officer Rene Haas — wants to become more of a chip supplier and less of a technology provider. But that makes it more of a rival to Qualcomm, which wants to differentiate its technology and cut reliance on Arm’s designs. Qualcomm, based in San Diego, acquired Nuvia to buttress its technology and offer more powerful chips tailored to high-end applications. It’s part of Qualcomm CEO Cristiano Amon’s plan to expand beyond the smartphone industry and grab a share of the laptop-chip market. Amon and Haas are slated to testify in the trial. This isn’t the first time Qualcomm has tussled with Arm. In 2020, Nvidia Corp. threw the companies into conflict when it announced plans for a $40 billion takeover of Arm. The deal sparked backlash from a variety of semiconductor firms and was ultimately abandoned in the face of regulatory opposition in the US, China and Europe. Among the opponents was Qualcomm, which complained to regulators around the world that Nvidia would prioritize its own use of Arm’s technology, or even cut off access to its competitors entirely. While Nvidia said such concerns were baseless and promised to maintain open access to Arm designs, those arguments ultimately won the day with regulators. Flex Its Power Arm’s move to cut off Qualcomm’s existing license is seen by the San Diego chipmaker as a way for the British company to flex its power over chip designs that are critical for much of the industry. Bloomberg Intelligence’s Tamlin Bason and Kunjan Sobhani have predicted the companies will settle the case before the jury reaches a verdict, with Qualcomm paying a higher licensing fee to access Arm’s technology. Yet when it comes to court fights, Qualcomm has a strong track record in computer-chip patent litigation. In 2019, it managed to secure a favorable settlement in a two-year licensing fight with Apple Inc. The Arm case is being heard in Delaware because Qualcomm is incorporated in the state — home to almost 70% of Fortune 500 companies. Delaware’s federal court also is a US hub of patent-infringement and licensing litigation. In 2021, that court was the country’s second-busiest patent forum, behind a federal court in west Texas. The case is Arm v. Qualcomm, 22-cv-01146, US District Court, District of Delaware (Wilmington). More stories like this are available on bloomberg.com ©2024 Bloomberg L.P.
Carson Beck completed 20 of 31 passes for 297 yards and four touchdowns as No. 10 Georgia pummeled UMass 59-21 on Saturday in Athens, Ga. Nate Frazier ran for career highs of 136 yards and three touchdowns, while Arian Smith caught three passes for 110 yards and a score as the Bulldogs (9-2) won their second straight game and 30th straight at home, dating back to 2019. AJ Hairston completed 7 of 16 passes for 121 yards and a score for the Minutemen (2-9), who dropped their third straight. Jalen John ran for 107 yards and a score and Jakobie Keeney-James caught three passes for 101 yards and a touchdown. Peyton Woodring kicked a 53-yard field goal to extend Georgia's lead to 31-14 on the first drive of the third quarter. But UMass wasted little time responding, as Hairston hit Keeney-James for a 75-yard touchdown to get the deficit down to 10. Georgia then finished its sixth straight drive with a score, as Frazier's 9-yard run up the middle gave the Bulldogs a 38-21 lead at the 8:44 mark of the third quarter. After UMass punted, Georgia played add-on in its next possession, with Frazier scoring from 15 yards out with 1:39 left in the third to lead 45-21. Frazier stamped his career day with his third touchdown run, a 2-yarder with 6:33 left, before Georgia capped the scoring with Chris Cole's 28-yard fumble return with 3:28 remaining. UMass took the game's opening drive 75 yards down the field -- aided by Ahmad Haston's 38-yard run -- and scored on CJ Hester's 1-yard run with 9:15 left. Georgia answered on its ensuing drive, as Beck's 17-yard passing touchdown to Oscar Delp tied the game at the 5:05 mark of the first quarter. Following a short punt by UMass, Beck connected with Smith for 49 yards, and a roughing-the-passer penalty put the ball at Minutemen's 14-yard line. Facing a fourth-and-4 from the 8-yard line, Beck found Cash Jones for a touchdown to take a 14-7 lead with 10:30 left in the second quarter. On UMass' next play from scrimmage, Raylen Wilson recovered John's fumble on the Minutemen's 28-yard line. Three plays later, Beck connected with Dominic Lovett for a 15-yard touchdown with 8:56 remaining. UMass then scored after a 14-play, 75-yard drive, finished off with John's 3-yard rushing score with 1:55 left in the first half. Georgia answered quickly, as Beck's 20-yard pass to Cole Speer set up a 34-yard touchdown pass to Smith with 43 seconds remaining, giving the Bulldogs a 28-14 halftime lead. --Field Level MediaWhat we know about the US drone sightings causing an online frenzy
MT lawmakers vote down bathroom rule change aimed at trans legislators
U.S. Coast Guard suspends search for missing 7-year-old after 2 bodies found in Gulf of MexicoLawmakers react to Hunter Biden pardonPrecision Strategies Vice President Rich Luchette and the Daschle Group Senior Vice President Joe Hack react to Bill Maher’s aggressive message for Democrats. "Real Time" host Bill Maher said he was considering quitting his political talk show because he couldn't handle another Donald Trump presidency. "I'm s---ting my pants. I may quit," Maher told his guest, actress and activist Jane Fonda, on his " Club Random " podcast on Sunday. "Because I don't want to do another [Trump term]." Maher boasted how he had warned Trump was a "con man" before the rest of the left started calling the President-elect a " threat to democracy ." "I did all the Trump stuff before anybody," he continued. "I've done it...I'm bored with it." HARRIS BACKER JANE FONDA RECALLS DOORS ‘SLAMMED IN HER FACE’ AS SHE BATTLES ‘PATRIARCHY’ "Real Time" host Bill Maher said the Democratic Party needs to look in the mirror following its Election Day defeat this week. (Screenshot/HBO) Fonda asked Maher if he could pivot to something else and not cover Trump instead. "The show is the politics. There is no other thing!" Maher replied. "And he’s going to dominate the news like he always does." Maher and Fonda went on to clash several times in the podcast over their disagreements about the prominence and problems the far-left posed to the Democratic Party. Maher, who has characterized himself as an "old school" liberal, argued with the far-left Fonda about regulations in California , gender ideology in schools, racism in America and how to address climate change. BEVERLY HILLS, CALIFORNIA - JUNE 28: Jane Fonda speaks for the "Destination Tomorrow: A Series Of Inspirational Keynotes" special talk during the 2024 Hollywood Climate Summit at Academy of Motion Picture Arts and Sciences on June 28, 2024 in Beverly Hills, California. ((Photo by Kevin Winter/Getty Images)) Fonda, who has been arrested for her climate activism , insisted that strong environmental regulations were needed because "we live in a soup of toxic chemicals" and "if we don't regulate it, we're all going to die of cancer." "That's true," Maher said, before arguing that many regulations were also not necessary. "You really don't believe the state we live in California is lacking regulations. There's over 300,000 regulations," he said. "Well, maybe they're needed," Fonda replied. NEWSOM PROPOSES $25M FROM STATE LEGISLATURE TO ‘TRUMP-PROOF’ CALIFORNIA Los Angeles, - September 25: Governor Gavin Newsom speaks at a press conference where he signs legislation related to oversight of oil and gas wells, and community protections on Wednesday, Sept. 25, 2024 in Los Angeles, . (Jason Armond / Los Angeles Times via Getty Images) (Jason Armond / Los Angeles Times via Getty Images) After sharing how he had to have three inspections in order to install a new garage door in his house, Maher complained California was over-regulated and over-taxed with "no checks on that sort of extreme leftism." Fonda disagreed, saying she didn't know California had this reputation. "I don't for a minute consider California a state that is extreme leftist. Not at all. Not any way," she said. The pair continued to spar after Maher called the NAACP "far left" for issuing a travel advisory to Florida for Black Americans last year, after Gov. Ron DeSantis banned funding for diversity, equity and inclusion programs at Florida's public universities. "There's stories like that, that just makes people roll their eyes and go, ‘Are you people nuts?’" he said before giving another example of progressives claiming men can "get pregnant." CLICK HERE FOR MORE COVERAGE OF MEDIA AND CULTURE Actress and activist Jane Fonda denied knowing about the "crazy things" the far-left said and did after being confronted by HBO host Bill Maher. (Adobe Stock) "I understand that a trans woman can get pregnant. That's different than a man getting pregnant. And the way they sort of like insist on blurring that line is if that's some sort of reasonable social cause as opposed to just being for having full rights, respect and protection for trans people?" he said. "I've never heard about men getting pregnant," Fonda shot back, saying Maher's was blowing out of proportion the "miniscule" amount of influence the far left had on the culture. They also clashed over their ideas on how to address climate change, with Fonda warning that Americans needed to cut all our emissions in half immediately to avoid an impending climate crisis. She argued that solar and wind, not "digging, fracking and mining," were the real solutions to solving this crisis. But Maher was critical of Fonda's suggestions, saying that radical clean energy measures were unlikely to get passed by lawmakers and that doomsday predictions about the end of the earth being near had come and passed several times before. CLICK TO GET THE FOX NEWS APP After several rounds of disagreement on political issues, Fonda told Maher she didn't believe they had a lot in common. "Your worldview is just so totally different than mine," she said. Kristine Parks is an associate editor for Fox News Digital. Read more.
Thank You For Your Support In 2024 #Thank #Your #Support #2024 #USA #Russia #Biden #Ukraine #War #Palestine #Gaza #Israel #Trump, Softbank CEO announce $100B investment in USColor-changing sensor offers new way to track motion and stress
Five teens arrested following attempted carjacking, assault at Towson Town Center, Baltimore County Police sayDiscussion On The Management Strategy And Profit Model Of Children’S PlaygroundMAI Capital Management trimmed its holdings in Cardinal Health, Inc. ( NYSE:CAH – Free Report ) by 75.5% during the third quarter, HoldingsChannel.com reports. The fund owned 4,269 shares of the company’s stock after selling 13,129 shares during the period. MAI Capital Management’s holdings in Cardinal Health were worth $472,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Other institutional investors and hedge funds have also recently bought and sold shares of the company. Pacer Advisors Inc. increased its stake in Cardinal Health by 9.9% in the second quarter. Pacer Advisors Inc. now owns 4,099,082 shares of the company’s stock valued at $403,022,000 after purchasing an additional 370,181 shares during the period. Price T Rowe Associates Inc. MD increased its position in Cardinal Health by 0.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,730,854 shares of the company’s stock valued at $305,584,000 after acquiring an additional 14,030 shares during the period. ProShare Advisors LLC raised its stake in Cardinal Health by 5.1% during the 2nd quarter. ProShare Advisors LLC now owns 1,759,299 shares of the company’s stock valued at $172,974,000 after acquiring an additional 85,247 shares during the last quarter. Renaissance Technologies LLC lifted its position in Cardinal Health by 7.1% during the 2nd quarter. Renaissance Technologies LLC now owns 1,683,447 shares of the company’s stock worth $165,517,000 after acquiring an additional 111,137 shares during the period. Finally, American Century Companies Inc. lifted its position in Cardinal Health by 17.7% during the 2nd quarter. American Century Companies Inc. now owns 1,610,968 shares of the company’s stock worth $158,390,000 after acquiring an additional 242,608 shares during the period. Hedge funds and other institutional investors own 87.17% of the company’s stock. Cardinal Health Stock Performance CAH opened at $121.84 on Friday. Cardinal Health, Inc. has a one year low of $93.17 and a one year high of $126.14. The company has a market cap of $29.49 billion, a price-to-earnings ratio of 23.70, a PEG ratio of 1.48 and a beta of 0.60. The business’s fifty day moving average is $113.90 and its two-hundred day moving average is $105.86. Cardinal Health Cuts Dividend The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be paid a $0.5056 dividend. This represents a $2.02 dividend on an annualized basis and a yield of 1.66%. The ex-dividend date is Thursday, January 2nd. Cardinal Health’s payout ratio is currently 39.30%. Wall Street Analysts Forecast Growth Several research firms have recently commented on CAH. Robert W. Baird upped their price target on Cardinal Health from $130.00 to $137.00 and gave the stock an “outperform” rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. upped their price objective on shares of Cardinal Health from $111.00 to $123.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. Mizuho boosted their price target on shares of Cardinal Health from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Cardinal Health from $119.00 to $124.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Finally, StockNews.com cut Cardinal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $123.00. Read Our Latest Stock Report on Cardinal Health Cardinal Health Company Profile ( Free Report ) Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. Further Reading Want to see what other hedge funds are holding CAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardinal Health, Inc. ( NYSE:CAH – Free Report ). Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter .
Growth investors have seen their fair share of bumps in the road the last few years, with some great businesses they follow being forced to navigate some real challenges. Several of these growth stocks managed their way through and are again delivering meaningful returns. If you have the investment capital and risk appetite to put cash into growth-oriented stocks, now might be a great time to put money into quality companies. As you determine which ones to invest in, it's important to only use cash that you won't soon need for monthly financial obligations and to ensure you thoroughly understand any company you buy before you add it to your basket of investments. With those elements in mind, here are two top growth stocks to consider that look like screaming buys in November. 1. TransMedics Group TransMedics Group ( TMDX -4.16% ) is a medical technology and devices company that focuses on organ transplant therapy for end-stage organ failure patients. The company was founded in 1998, and one of the achievements that the company is most known for is its Organ Care System (OCS). The TransMedics OCS is a device that enables the maintenance and preservation of donor organs from storing to transporting those organs to transplant patients. The device can perform numerous functions, including imitating the temperature of the human body and transmitting nutrients to keep the donor organ healthy. Three types of organs can be preserved and stored in the TransMedics OCS -- lungs, livers, and hearts. The OCS can maintain the health of organs outside of the human body for up to 24 hours in many cases. With traditional cold storage methods that have historically been used to facilitate organ transplants, numerous complications regularly ensue ranging from ischemia to enhanced complications post-transplant. Ischemia is a common issue with organ transplants that occurs when insufficient blood flow to the donor organ causes damage to the tissue that can deteriorate further after the transplant. With the TransMedics OCS, the risk of ischemia is greatly reduced, as is the risk of potential complications. Another integral aspect to TransMedic Group's growth strategy is its logistics business, which even includes an air fleet that it uses to transport donor organs. TransMedics had 18 owned aircraft in its fleet at last count. Management believes that the company is on track to achieve the goal of 10,000 OCS transplant cases per year in the U.S. by 2028. Total revenue in the third quarter of 2024 totaled approximately $109 million, a 64% increase from one year ago. Management noted that this revenue growth was driven by continued adoption of its OCS across all three organs as well as logistics revenue. Where TransMedics Group reported a net loss of $25.4 million one year ago, the recent quarter saw it generate net income of $4.2 million. Management is also forecasting anywhere from 76% to 84% revenue growth in the full year 2024 compared to 2023. Investors who want to become part-owners in an innovative business disrupting the multibillion-dollar global transplant market might want to take a second look at this healthcare stock . 2. Shopify Shopify ( SHOP 0.45% ) has built an explosive global footprint since the company was first founded nearly two decades ago. The company controls about 10% of the global e-commerce software market and is the largest e-commerce software platform in the U.S. with a market share of roughly 30%. Bear in mind that the U.S. e-commerce market is valued north of $1 trillion. It is the largest e-commerce market in the world second only to China. Shopify's market opportunity is only growing both in its core North American markets and internationally as the global e-commerce industry expands. In the third quarter of 2024, Shopify reported its fifth consecutive quarter of gross merchandise value (GMV) growth, which is the total value of merchandise sold in a given period. Gross payment volume (GPV) is also accelerating at a rapid clip. Its operating income more than doubled in Q3, while revenue growth accelerated 26% year over year to $2.2 billion. Shopify's suite of software and hardware solutions are known for integrations with a wide range of offerings from its global partner ecosystem. However, its own in-house solutions, such as Shopify Payments (a payment processing service for merchants) and Shop Pay (a seamless checkout option for customers) are proving to be key growth drivers. Case in point: The Shopify Payments offering processed $43 billion in GPV in the third quarter of 2024, a whopping 31% increase from one year ago that accounted for 62% of overall GMV. As for Shop Pay, this product offering processed $17 billion in GMV in Q3, a 42% year-over-year increase that comprised 41% of GPV. Shopify remains very profitable, with Q3 operating income soaring 132% to $283 million and net income rising 15% from one year ago to $828 million. It also delivered a 19% free cash flow margin, with total free cash flow exploding 53% year over year to $421 million. While some investors may shy away from e-commerce given the current growth environment, Shopify is proving that it's a comeback kid. It definitely isn't too late to snag some shares that can compound your returns generously over the next five or more years.
By HALELUYA HADERO, Associated Press President-elect Donald Trump asked the Supreme Court on Friday to pause the potential TikTok ban from going into effect until his administration can pursue a “political resolution” to the issue. The request came as TikTok and the Biden administration filed opposing briefs to the court, in which the company argued the court should strike down a law that could ban the platform by Jan. 19 while the government emphasized its position that the statute is needed to eliminate a national security risk. “President Trump takes no position on the underlying merits of this dispute. Instead, he respectfully requests that the Court consider staying the Act’s deadline for divestment of January 19, 2025, while it considers the merits of this case,” said Trump’s amicus brief, which supported neither party in the case. The filings come ahead of oral arguments scheduled for Jan. 10 on whether the law, which requires TikTok to divest from its China-based parent company or face a ban, unlawfully restricts speech in violation of the First Amendment. Earlier this month, a panel of three federal judges on the U.S. Court of Appeals for the District of Columbia Circuit unanimously upheld the statute , leading TikTok to appeal the case to the Supreme Court. The brief from Trump said he opposes banning TikTok at this junction and “seeks the ability to resolve the issues at hand through political means once he takes office.”